Education
About Us
Working with TipRanks
Follow Us
Targovax Asa (GB:0RIS)
:0RIS
0RIS Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr0.60 - kr10.75
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
kr68.24M
Enterprise Valuekr60.17M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)0.1
Beta0.91
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding108,841,740
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Targovax ASA News
0RIS FAQ
What was Targovax Asa’s price range in the past 12 months?
Targovax Asa lowest share price was kr0.60 and its highest was kr10.75 in the past 12 months.
What is Targovax Asa’s market cap?
Targovax Asa’s market cap is kr68.24M.
When is Targovax Asa’s upcoming earnings report date?
Targovax Asa’s upcoming earnings report date is Aug 20, 2026 which is in 320 days.
How were Targovax Asa’s earnings last quarter?
Targovax Asa released its earnings results on Aug 28, 2025. The company reported -kr0.262 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.262.
Is Targovax Asa overvalued?
According to Wall Street analysts Targovax Asa’s price is currently Overvalued.
Does Targovax Asa pay dividends?
Targovax Asa does not currently pay dividends.
What is Targovax Asa’s EPS estimate?
Targovax Asa’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Targovax Asa have?
Targovax Asa has 108,841,740 shares outstanding.
What happened to Targovax Asa’s price movement after its last earnings report?
Targovax Asa reported an EPS of -kr0.262 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Targovax Asa?
Currently, no hedge funds are holding shares in GB:0RIS
Company Description
Targovax Asa
Targovax ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer.